Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
J. H. Kim, S. H. Kim, M. K. Jeon, J. E. Kim, K. H. Kim, K. -H. Yun, H. -C. Jeung, S. Y. Rha, J. -H. Ahn, H. S. Kim
Summary: Combination therapy with pemetrexed and cisplatin showed clinically meaningful and sustained responses among patients with advanced and refractory soft tissue sarcomas, meeting its predefined primary study endpoint.
Article
Oncology
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara
Summary: This phase III randomized study compared the efficacy of cisplatin plus gemcitabine and cisplatin plus pemetrexed in the treatment of advanced non-small-cell lung cancer (NSCLC). The results showed that cisplatin plus pemetrexed was noninferior to cisplatin plus gemcitabine in terms of overall survival. However, cisplatin plus pemetrexed showed superior survival in patients with adenocarcinoma and large-cell carcinoma histology, while cisplatin plus gemcitabine was more effective in patients with squamous cell histology. Cisplatin plus pemetrexed also had less adverse reactions and more convenient administration.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Peter H. O'Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Helen H. Moon, Terence W. Friedlander, Rana R. McKay, Mehmet A. Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg
Summary: EV + Pembro demonstrated a high confirmed objective response rate (cORR) with durable responses as a first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC). Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Fumihiko Kinoshita, Yuka Oku, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Fumihiro Shoji, Tatsuro Okamoto
Summary: The efficacy and safety of N + GC in the second-line or later treatment of LSCC patients have been proven. However, the management of adverse events is essential.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Gastroenterology & Hepatology
Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh
Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.
Article
Oncology
Dingwei Ye, Jiyan Liu, Aiping Zhou, Qing Zou, Hanzhong Li, Cheng Fu, Hailong Hu, Jian Huang, Shaoxing Zhu, Jie Jin, Lulin Ma, Jianming Guo, Jun Xiao, Se Hoon Park, Dahong Zhang, Xiusong Qiu, Yuanyuan Bao, Lilin Zhang, Wei Shen, Feng Bi
Summary: Tislelizumab showed meaningful clinical benefits in patients with previously treated PD-L1-positive urothelial carcinoma, with a 24% objective response rate and a durable response rate of 68%. The most common adverse events were anemia and pyrexia.
Article
Oncology
Timil H. Patel, Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Robert N. Schuck, Yangbing Li, Xinyuan Zhang, Jeanne Fourie Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J. Lemery, Richard Pazdur, Marc R. Theoret, Lola A. Fashoyin-Aje
Summary: The FDA has granted accelerated approval to pemigatinib for the treatment of previously treated advanced or metastatic cholangiocarcinoma with an FGFR2 fusion. The approval was based on a clinical trial showing an overall response rate of 36% and a median duration of response of 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, and nail toxicity.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Thomas J. George, Alison M. Ivey, Azka Ali, Ji-Hyun Lee, Yu Wang, Karen C. Daily, Brian H. Ramnaraign, Sanda A. Tan, Krista P. Terracina, Thomas E. Read, Long H. Dang, Atif Iqbal
Summary: The study investigated the combination therapy of sorafenib and capecitabine in refractory metastatic colorectal cancer, showing a median progression-free survival of 6.2 months with manageable toxicity. This oral doublet therapy warrants further investigation for clinical use in patients with mCRC.
Article
Oncology
Wendy Munoz-Montano, Sae Muniz-Hernandez, Alejandro Aviles-Salas, Rodrigo Catalan, Luis Lara-Mejia, Suraj Samtani-Bassarmal, Andres F. Cardona, Jorge Mendoza-Desion, Daniel Hernandez-Cueto, Altagracia Maldonado, Guillermina Baay-Guzman, Sara Huerta-Yepes, Oscar Arrieta
Summary: The study conducted immunohistochemistry semi-quantitative analysis on four biomarkers (ERCC1, RRM1, RRM2, and hENT-1) to predict treatment response in advanced MPM patients receiving continuous infusion gemcitabine plus cisplatin, showing that ERCC1 and RRM1 are useful biomarkers for predicting better survival outcomes.
Article
Oncology
Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Hirotoshi Iihara, Kei Kawada, Takafumi Nakano, Takashi Egawa
Summary: Patients with lung cancer undergoing carboplatin plus pemetrexed (CBDCA+PEM) chemotherapy have a higher risk of delayed nausea compared to those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy, while the incidence of vomiting does not significantly differ between the two groups. Female sex, younger age, and CBDCA+PEM regimen are independent risk factors for delayed nausea, while female sex is an independent risk factor for delayed vomiting.
Article
Pharmacology & Pharmacy
Xia Luo, Zhen Zhou, Xiaohui Zeng, Qiao Liu
Summary: The objective of this study was to investigate the cost-effectiveness of adding the Chinese-developed anti-PD-1 antibody tislelizumab to first-line pemetrexed-platinum chemotherapy in Chinese patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) without known sensitizing EGFR mutations or ALK rearrangements. The results showed that adding tislelizumab to first-line chemotherapy was cost-effective regardless of the patients' baseline characteristics.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Norikazu Matsuo, Takaaki Tokito, Tomoaki Hoshino
Summary: This retrospective study investigated the effectiveness of atezolizumab plus carboplatin and etoposide in SCLC patients previously treated with platinum-based chemotherapy, revealing significant efficacy for patients with refractory and sensitive relapse. It may serve as a second-line treatment option for SCLC patients who have undergone platinum-based chemotherapy.
INVESTIGATIONAL NEW DRUGS
(2021)
Review
Gastroenterology & Hepatology
Daniel Walden, Cody Eslinger, Tanios Bekaii-Saab
Summary: Biliary tract cancers, a diverse and aggressive malignancy, have a poor prognosis and limited treatment options. However, advancements in genetic sequencing have opened up new avenues for targeted therapy in this field.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Article
Medicine, Research & Experimental
Yi Chen, Haiming Yu, Chao Wu, Jinyu Li, Shunchang Jiao, Yi Hu, Haitao Tao, Baishou Wu, Aijie Li
BIOMEDICINE & PHARMACOTHERAPY
(2016)
Article
Oncology
Youchao Jia, Zhigang Wang, Aimin Zang, Shunchang Jiao, Sumei Chen, Yan Fu
INTERNATIONAL JOURNAL OF ONCOLOGY
(2016)
Article
Oncology
Yanfang Ju, Shengjie Sun, Jinliang Wang, Shunchang Jiao
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2016)
Article
Multidisciplinary Sciences
Xiaojie Xu, Zhongyi Fan, Chaoyang Liang, Ling Li, Lili Wang, Yingchun Liang, Jun Wu, Shaohong Chang, Zhifeng Yan, Zhaohui Lv, Jing Fu, Yang Liu, Shuai Jin, Tao Wang, Tian Hong, Yishan Dong, Lihua Ding, Long Cheng, Rui Liu, Shenbo Fu, Shunchang Jiao, Qinong Ye
NATURE COMMUNICATIONS
(2017)
Article
Oncology
Yi Chen, Jinyu Li, Yibao Zhang, Yi Hu, Guoqing Zhang, Xiang Yan, Zhi Lin, Zhifei Zhao, Shunchang Jiao
STRAHLENTHERAPIE UND ONKOLOGIE
(2018)
Article
Oncology
Liangliang Wu, Hongyu Liu, Hongchuan Guo, Qiong Wu, Songyan Yu, Yuanyuan Qin, Gang Wang, Qiyan Wu, Rong Zhang, Lingxiong Wang, Lijun Zhang, Chunxi Liu, Shunchang Jiao, Tianyi Liu
Article
Oncology
Jiasen Xie, Zishan Zhou, Shunchang Jiao, Xiaokun Li
Article
Immunology
Zhi-Min Wei, Zhuo Wang, Xiao-Jian Wan, Xian-Jing Li, Yi-Xing Li, Yang Bai, Xue Yang, Yong Yang, Shun-Chang Jiao, Zhe-Feng Liu
IMMUNOLOGIC RESEARCH
(2019)
Article
Gastroenterology & Hepatology
Ying Xiong, Qian-Qian Chen, Ning-Li Chai, Shun-Chang Jiao, En-Qiang Ling Hu
WORLD JOURNAL OF GASTROENTEROLOGY
(2019)
Article
Oncology
Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Yu Wang, Zhongyi Fan, Shengsheng Yang, Shunchang Jiao
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2018)
Article
Multidisciplinary Sciences
Yuanmei Dong, Yang Liu, Hui Bai, Shunchang Jiao
SCIENTIFIC REPORTS
(2019)
Article
Oncology
Bo Yang, Xiao Zhao, Chong Wan, Xin Ma, Shaoxi Niu, Aitao Guo, Jieli Wang, Jinliang Wang, Decong Sun, Shunchang Jiao
Summary: This study investigated the genomic features of Chinese urothelial carcinoma (UC) patients and found significant genetic alterations differences between UTUC and UCB. It also identified a reasonably good concordance of genomic features between circulating tumor DNA (ctDNA) and tissue samples.
Article
Oncology
Jingjing Duan, Haiyang Zhang, Shuang Li, Xinyi Wang, Haiou Yang, Shunchang Jiao, Yi Ba
CANCER CELL INTERNATIONAL
(2017)
Article
Medicine, Research & Experimental
Wushuang Du, Shuofeng Hu, Shangli Cai, Yu Wang, Liangliang Wu, Danyang Sun, Shunchang Jiao, Yi Hu
DISCOVERY MEDICINE
(2018)